This study found that using GLP-1 RAs and SGLT2is for type 2 diabetes treatment offers potential neuroprotections against Alzheimer disease and related dementias. HealthDay News — Both glucagon ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

THURSDAY, April 17, 2025 (HealthDay News) — Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them ...

This certification facilitates the identification of patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma who may benefit from KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back ...

This certification facilitates the identification of patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma who may benefit from KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy ...

A once-daily oral GLP-1 conferred greater reductions in HbA1c and body weight than placebo among adults with type 2 diabetes, according to top-line results from the ACHIEVE-1 trial announced by ...

Dry eye syndrome is a common complication of both type 1 and type 2 diabetes. It happens because of high blood sugars. When your blood sugar is high, it can cause nerve damage in your eyes which ...